Allena Pharmaceuticals, Inc. Current Ratio

Current Ratio of ALNA for past 10 years: annual, quarterly and twelve month trailing (TTM) including Current Ratio growth rates and interactive chart. The current ratio is a liquidity ratio that measures whether a firm has enough resources to meet its short-term obligations. It is calculated as current assets divided by current liabilities. A ratio below 1 indicates potential trouble for a company, as it doesn't have enough current assets to pay for its short-term liabilities. A ratio above 2 is usually considered healthy.

Highlights and Quick Summary

  • Current Ratio for the quarter ending March 31, 2022 was 2.0 (a -5.16% decrease compared to previous quarter)
  • Year-over-year quarterly Current Ratio decreased by -45.03%
  • Annual Current Ratio for 2021 was 2.11 (a -65.4% decrease from previous year)
  • Annual Current Ratio for 2020 was 6.08 (a 100.9% increase from previous year)
  • Annual Current Ratio for 2019 was 3.03 (a -72.93% decrease from previous year)
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Current Ratio of Allena Pharmaceuticals, Inc.

Most recent Current Ratioof ALNA including historical data for past 10 years.

Interactive Chart of Current Ratio of Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals, Inc. Current Ratio for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 2.0
2021 2.11 5.47 3.63 5.71 2.11
2020 6.08 7.99 4.21 2.84 6.08
2019 3.03 3.96 6.8 7.83 3.03
2018 11.19 14.73 29.27 12.05 11.19
2017 12.73 4.83 12.73
2016 15.16
2015 13.62 13.6

Business Profile of Allena Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.